KINS Inc. Joins 'Innovation Infusion Japan (i2.JP)'

KINS Inc. (Location: Koto-ku, Tokyo; Representative: Yutaka Shimokawa; hereafter "KINS") has agreed with the activity philosophy of the open innovation network "Innovation Infusion Japan (i2.JP)" led by AstraZeneca K.K. (Headquarters: Kita-ku, Osaka; Representative Director and President: Takashi Horii; hereafter "AstraZeneca") and has joined as a partner company.

With a mission to "free the world from chronic diseases and symptoms through the power of bacteria," KINS is a microbiome-specialized health-tech company that develops a unique business model integrating products, clinics, and research.

Through its participation in i2.JP, KINS will further accelerate co-creation with diverse stakeholders, including startups, healthcare professionals, academia, and local governments. By collaborating with pharmaceutical companies, medical institutions, and other partner companies to implement solutions utilizing KINS's proprietary data into society, the company intends to contribute to solving healthcare challenges through microbiome insights.

■ About Innovation Infusion Japan (i2.JP)

i2.JP is an open innovation network developed by AstraZeneca that connects startups, healthcare professionals, local governments, academia, and private companies. It aims to address problems in the healthcare field and collectively create practical, optimal solutions through collective intelligence.

The network challenges four missions that are difficult to achieve by a single organization or individual: realizing "patient-centricity," providing added value to healthcare professionals, discovering and nurturing new technologies, and optimizing medical systems.

For more details, please visit the official website below.

Official Website: https://www.i2jp.net/

■ About KINS

KINS Inc. is a microbiome-specialized health-tech company with a mission to "free the world from chronic diseases and symptoms through the power of bacteria." Its strength lies in combining expertise in both medical specialization and B2C marketing. The company integrates three businesses: a product business targeting men and women with a total of over 120,000 users; a clinic business that serves as a site for the treatment and clinical research of bacteria-related chronic diseases and symptoms (two veterinary clinics in Japan and one human clinic in Singapore); and a drug discovery business aimed at developing new treatments for chronic diseases and symptoms using data and specimens obtained from both businesses. KINS aims to free more people—men, women, and animals—from various chronic diseases and symptoms associated with bacteria.

■ Company Overview

Company Name: KINS Inc.

Address: 1-17-8-328 Shinkiba, Koto-ku, Tokyo

Representative: Yutaka Shimokawa

Business Description: Product business, clinic business, and drug discovery business based on microbiome research

Official Website: https://corporate.yourkins.com/